Oxford BioDynamics Plc Receives Queen’s Award for Enterprise, the UK’s highest accolade for business success

Christian Hoyer Millar, Chief Executive Officer of Oxford BioDynamics, said:

“We are delighted to have been chosen for such a prestigious award, which is an outstanding achievement for the Company. This award is recognised worldwide as a standard of enterprise excellence, reflecting the hard work and commitment shown by our team over the years in developing real-world solutions to unmet clinical needs of high priority. I’d like to extend my thanks to everyone at OBD for their part in this achievement.

The award is a wonderful recognition of the value OBD and its EpiSwitch™ platform has generated, but also an acknowledgement of the innovative environment at the University of Oxford, from where OBD was spun-out. Together, we are helping to bring critical solutions onto the world stage.”

Oxford BioDynamics Plc (LON:OBD) is delighted to announce that it has today been recognised as a winner of the 2019 Queen’s Award for Enterprise, the most prestigious enterprise award given to UK businesses. The Company has been granted the Queen’s Award for Enterprise in Innovation, demonstrating the outstanding performance and commercial success of OBD’s proprietary technology platform, EpiSwitch™, based on the latest advances in regulatory genome architecture and its functional links to patient stratifications and outcomes in oncology, neurodegenerative, inflammatory, metabolic and other indications.

EpiSwitch™ is an innovative technology platform for the discovery, evaluation, validation and monitoring of a novel class of epigenetic biomarkers known as “chromosome conformation signatures”. These biomarker signatures can provide a compelling, stable framework from which changes in the regulation of a genome can be analysed, long before the results of these epigenetic changes manifest themselves as obvious abnormalities.

Validated EpiSwitch™ biomarker applications have demonstrated high efficacy in predictive, prognostic and diagnostic patient stratifications for lung, haematological, prostate, thyroid and skin cancers, as well as in rheumatoid arthritis, and amyotrophic lateral sclerosis. Baseline predictive stratifications by EpiSwitch™ for response to immune-checkpoint inhibitors are excellent surrogates for standard primary endpoints used in clinical trials, such as progression free survival. The Company has recently entered into its fifth collaboration agreement with a leading pharmaceutical company for the development of predictive biomarkers for immuno-oncology therapeutics. To date, EpiSwitch™ has been used to develop biomarkers on more than 6,500 blood samples in over 140 diverse projects.

The EpiSwitchTM platform is designed to accelerate drug discovery and development processes, improve success rates of therapeutic candidates, and reduce the overall cost of therapeutic development and health-care infrastructure by enabling precision medicine initiatives and empowering informed clinical decision-making.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Share on facebook
    Facebook
    Share on twitter
    Twitter
    Share on linkedin
    LinkedIn
    Oxford BioDynamics

    More articles like this

    Oxford BioDynamics

    How are EpiSwitch markers detected?

    Introduction: Getting the basics right Oxford BioDynamics’ (OBD) EpiSwitch™ biomarker discovery platform combined with their newly enhanced detection technology gives the company valuable quantitative insights into chromosome conformations (DNA protein complexes) that regulate normal and disease biology in

    Oxford BioDynamics

    What is EpiSwitchTM and how is it used?

    Oxford BioDynamics’ EpiSwitch™ technology is based on epigenetics, mechanisms that alter gene expression without altering the underlying DNA sequence and whose deregulation plays a role in the development of cancer, autoimmune, and neurologic diseases. Although DNA is often

    Oxford BioDynamics

    Sanders-Brown research highlights form of severe dementia

    The long-running study on aging and brain health at the University of Kentucky’s Sanders-Brown Center on Aging (SBCoA) Alzheimer’s Disease Center has once again resulted in important new findings – highlighting a complex and under-recognized form of dementia.

    Oxford BioDynamics

    Researchers identify new genetic defect linked to ALS

    Mutations in the UBQLN2 gene, known to cause amyotrophic lateral sclerosis (ALS), promote the buildup of toxic waste in brain cells by preventing the normal function of two cellular degradation mechanisms, a study has found. In addition to its known role in the proteasome,

    Oxford BioDynamics

    New questions about Covid-19

    The coronavirus is known with certainty that it emerged in China in November and has since spread to almost the entire world, where it has infected more than 5 million people and killed at least 356,000. Older adults are more at risk,

    Oxford BioDynamics

    EpiSwitch technology selected as biomarker platform for COVID-19

    Oxford BioDynamics’ EpiSwitch technology has been chosen as the biomarker platform for prognostic and predictive profiling of COVID-19 patients in the GETAFIX clinical study.Institute of Infection, Immunity and Inflammation, University of Glasgow, and NHS Scotland are leading the

    Oxford BioDynamics

    Rare Diseases Clinical Research Network Opens Online Survey on COVID-19

    The Rare Diseases Clinical Research Network (RDCRN) has opened an online survey to better understand how the COVID-19 outbreak is affecting people with rare diseases, their families, and caregivers. Survey questions cover a patient’s physical and mental health, supply of treatments, and access to

    Oxford BioDynamics

    Pandemic moves ALS Awareness Month events and activities online

    ALS Awareness Month has been observed each May since 1992. But this year, the COVID-19 pandemic has forced supporters to rethink ways to raise funds and awareness for amyotrophic lateral sclerosis (ALS). In previous years, May has been full of fundraising and educational activities such as

    Oxford BioDynamics

    ALS Awareness

    “I think it’s time we stop, children, what’s that sound? Everybody look what’s going down.” That call for awareness comes from the song “For What It’s Worth” by Buffalo Springfield. The song’s writer, Stephen Stills, penned the lyrics in response to

    Oxford BioDynamics

    ALS Awareness Month This May

    Within weeks following my ALS diagnosis, I faced my first ALS Awareness Month. At the time, I was still figuring out exactly what I had and how to pronounce amyotrophic lateral sclerosis. Never mind trying to educate others about it. I hated the letters

    Oxford BioDynamics

    Microarray Facility

    The purpose-built Oxford Biodynamics Array facility offers a complete sample processing service for Comparative Genome Hybridization (CGH) using the Agilent microarray platform.  Agilent’s flexible SurePrint technology produces high-quality arrays of 60-mer oligonucleotides in a range of multiplex formats

    Oxford BioDynamics

    EpiSwitch biomarker discovery platform

    INTRODUCTION • The EpiSwitch biomarker discovery platform detects systemic changes in the cellular genomic architecture using a microarray and PCR-based biomarker platform (Figure 1)1. It identifies and monitors chromosome conformation signatures (CCSs), key regulatory processes that integrate environmental

    No more posts to show